NGEN logo

NERVGEN PHARMA CORP

NGENNASDAQ
Earnings Nov 12US Equity
$1.92▲ $0.04 (+2.13%)
🌅 Pre-market$1.91▼ 0.50%Regular close · extended-hours price shown
🔔
Track NGEN
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 2.1%
7d▼ 2.0%
14d▼ 9.0%
30d▼ 13.9%
ytd—
1y—
🏦Market Cap
$204M
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
—
Otter Score
72
Fair

Trading Snapshot

Day Range
$1.91 – $1.94
52-Week Range
—
Volume
$4.74B
Avg Volume
$4.31B
Shares Outstanding
106.2M
Next Earnings
Oct 23, 2026

Fundamentals Snapshot

Annual Revenue
$22M
Last Q Revenue
$6M
P/E Ratio
—
P/S Ratio
—
EPS (TTM)
—
Dividend Yield
—
Dilution (1yr)
+2.8%

Why Investors Own NGEN

  • ✓High-growth profile — revenue up +1.4% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 78% gross margin and 24% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

NGEN logo

NERVGEN PHARMA CORP

NGEN
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$25M▲ +0.7% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$19M▲ +15.9% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
72.3M▲ +2.8% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$22M▲ +$5M YoY
StockOtter · stockotter.space

About NERVGEN PHARMA CORP

NervGen Pharma Corp. is a biotechnology enterprise currently in its clinical development phase, focused on devising therapeutic solutions for nerve injuries and progressive neurodegenerative diseases. Their innovative approach centers on deactivating the natural biological mechanisms that typically impede the nervous system's ability to repair itself.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Fair
72/100

Analyst Ratings

ⓘ
Consensus
Buy
8 analysts
Strong Buy1
Buy6
Hold1
Sell0
Strong Sell0
Ratings as of Jul 2026

Latest News & Updates

GlobeNewsWire·4d ago

NervGen to Restate Previously Filed Financial Statements Recognizing Non-Cash Accounting Adjustments

VANCOUVER, British Columbia, Sept. 25, 2026 (GLOBE NEWSWIRE) -- NervGen (NASDAQ: NGEN), a late-stage clinical biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI)

GlobeNewsWire·21d ago

NervGen to Host Inaugural R&D Day on September 30, 2026

VANCOUVER, British Columbia, Sept. 09, 2026 (GLOBE NEWSWIRE) -- NervGen (NASDAQ: NGEN), a late-stage clinical biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI)

GlobeNewsWire·Aug 13

NervGen Reports Second Quarter 2026 Financial Results and Provides Business Updates

VANCOUVER, British Columbia, Aug. 13, 2026 (GLOBE NEWSWIRE) -- NervGen (NASDAQ: NGEN), a late-stage clinical biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) a

Seeking Alpha·Jul 2

NervGen Pharma: I Think The Biggest Risks Are Now Behind It

NervGen Pharma remains a Buy, with reduced regulatory, financing, and execution risks following FDA alignment on the Phase 3 RESTORE trial. NGEN's recent $60M capital raise secures funding for its pivotal trial, shifting